Closed System Transfer Devices Market Size, Share, Status and Prospects 2022 to 2032

Posted by Ganesh Shinde on November 1st, 2022

The global Closed System Transfer Devices market was worth USD 872 million in 2022, and it is expected to grow at an 18.1% CAGR over the forecast period to reach USD 3800 million by 2032.

A closed system transfer device, also known as a 'CSTD,' is a drug transfer device that mechanically restricts the transfer of environmental contamination within the medical system as well as the escape of hazardous drug or vapour concentrations outside the system. To maintain the sterility of a fluid pathway, open versus closed systems are commonly used in medical devices. CSTDs prevent the uncontrolled inflow and outflow of contaminants and drugs, thereby preserving the quality of the solution to be infused into a patient. These devices protect healthcare workers when they are exposed to hazardous drugs or chemicals.

In recent years, closed system transfer device designs and models have changed at a rapid pace, resulting in the development of a number of independent testing methodologies to assess closed system transfer device performance. Manufacturers in the closed system transfer devices market are currently focusing more on meeting performance requirements, which are primarily concerned with patient safety and sterile practises.

Market trends and drivers: Include the increasing use of CSTDs to combat the harmful effects of cytotoxic and antineoplastic drugs. Antineoplastic drugs are widely used in cancer treatment and are considered dangerous drugs. Healthcare workers who prepare, transport, distribute, administer (pre and post-administration), and dispose of these drugs are extremely vulnerable.

The National Institute for Occupational Safety and Health (NIOSH) recommends using CSTDs to eliminate the harmful effects caused by hazardous substances that escape from the system during drug preparation and administration. CSTDs act as a barrier, preventing contaminants from being transferred from the atmosphere to a sterile environment. Because of these benefits, CSTDs are increasingly being used in healthcare facilities to combat the negative effects of dangerous drugs. Chemotherapy, a popular cancer treatment, employs one or more antineoplastic drugs to kill abnormal cells in patients. When preparing, transporting, administering, and disposing of hazardous drugs, the use of closed system transfer devices (CSTDs) in conjunction with other safety precautions such as gloves, gowns, masks, and vented preparation hoods is an effective way to increase safety. With the rising prevalence of cancer and the increased use of chemotherapy treatments, the demand for CSTDs is expected to rise in the coming years.

COVID-19 Impact: The COVID-19 outbreak reduced demand for CSTDs during the first two quarters of 2020. Due to virus containment norms and nationwide lockdowns, hospital patient footfalls were limited, primarily due to COVID-19 and emergency cases. Elective medical procedures are on hold, causing a downward shift in demand for CSTDs. Nonetheless, with the decline in the number of active COVID-19 cases and the economic recovery in developed countries, more use of these devices may be expected in the near future.

B. Braun Holding GmbH & Co. KG, Baxter International, Becton, Dickinson and Company, Caragen Ltd, Corvida Medical, Equashield, FIMI Opportunity Funds (Simplivia Healthcare), ICU Medical, JCB Co Ltd. (JMS Co Ltd.), and Yukon Medical are the key players in the closed system transfer devices market.

Browse More@ https://www.futuremarketinsights.com/reports/closed-system-transfer-devices-market